FDA grants Sanofi's blockbuster priority review in a new indication

Sanofi’s drug Dupixent has now received the US health authority’s Breakthrough Therapy, Orphan Drug and Priority Review designations, the latter of which in a new indication for people with inflamed esophagi due to allergies.
Photo: Benoit Tessier/Reuters/Ritzau Scanpix
Photo: Benoit Tessier/Reuters/Ritzau Scanpix
by CHRISTIAN BUNDGAARD, translated by daniel pedersen

French Sanofi has been granted Priority Review by the US Food and Drug Administration (FDA) for Dupixent (dupilumab) in the indication for eosinophilic esophagitis (EoE), an inflammatory disease of the esophagus, the company has announced in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading